Outlier in a BE study [Outliers]

posted by riteshsrmc  – India, 2014-01-16 13:44 (3751 d 21:02 ago) – Posting: # 12177
Views: 9,483

Hi Auditor,

By the way to which agency you are filing the product? Agreed with Dan! EMEA has clearly defined the situation in guidance. I would suggest you to look at FDA perspective as well, if you are filing to FDA. FDA does not encourage redosing to handle outliers subjects incase of non-replicate design study wherein you may carry out redosing incase of replicate design. You should be clear they way agency look at the data with or without outliers.

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,655 registered users;
124 visitors (0 registered, 124 guests [including 5 identified bots]).
Forum time: 11:47 CEST (Europe/Vienna)

Never never never never use Excel.
Not even for calculation of arithmetic means.    Martin Wolfsegger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5